2 completed, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow MSC1992371A: new trials by email Literature Review of MSC1992371A trials Research Report on MSC1992371A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AS703569 and Gemcitabine Combination in Advanced Malignancies AS703569/gemcitabine - Pancreatic Cancer | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 66 | 2007-06-01 | 2014-01-30 |
| A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies AS703569 - Haematological Malignancies | Phase 1 | Terminated | EMD Serono | 124 | 2006-12-01 | 2013-10-22 |
| AS703569 Phase I in Patients With Solid Tumours AS703569 - Solid Tumors | Phase 1 | Completed | EMD Serono | 104 | 2006-08-01 | 2014-01-30 |
EMD Serono (2) · Merck KGaA, Darmstadt, Germany (1)
Belgium (2) · United States (2) · France (1) · Germany (1) · Italy (1) · Switzerland (1)
Narmyn Rejeb, MD (2) · Narmyn Rejeb, M.D. (1)